AC IMMUNE SA (ACIU) Stock Fundamental Analysis

NASDAQ:ACIU • CH0329023102

2.63 USD
+0.01 (+0.38%)
Last: Feb 19, 2026, 04:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ACIU scores 2 out of 10 in our fundamental rating. ACIU was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of ACIU have multiple concerns. ACIU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ACIU has reported negative net income.
  • In the past year ACIU has reported a negative cash flow from operations.
  • In the past 5 years ACIU always reported negative net income.
  • In the past 5 years ACIU reported 4 times negative operating cash flow.
ACIU Yearly Net Income VS EBIT VS OCF VS FCFACIU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • ACIU has a Return On Assets (-41.88%) which is in line with its industry peers.
  • ACIU has a Return On Equity (-115.10%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.88%
ROE -115.1%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ACIU Yearly ROA, ROE, ROICACIU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACIU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACIU Yearly Profit, Operating, Gross MarginsACIU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ACIU has been increased compared to 1 year ago.
  • The number of shares outstanding for ACIU has been increased compared to 5 years ago.
  • ACIU has a worse debt/assets ratio than last year.
ACIU Yearly Shares OutstandingACIU Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACIU Yearly Total Debt VS Total AssetsACIU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • ACIU has an Altman-Z score of -3.58. This is a bad value and indicates that ACIU is not financially healthy and even has some risk of bankruptcy.
  • ACIU's Altman-Z score of -3.58 is in line compared to the rest of the industry. ACIU outperforms 45.11% of its industry peers.
  • ACIU has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • ACIU has a Debt to Equity ratio of 0.06. This is comparable to the rest of the industry: ACIU outperforms 40.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -3.58
ROIC/WACCN/A
WACC4.92%
ACIU Yearly LT Debt VS Equity VS FCFACIU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • ACIU has a Current Ratio of 1.16. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
  • ACIU has a Current ratio of 1.16. This is amonst the worse of the industry: ACIU underperforms 84.26% of its industry peers.
  • ACIU has a Quick Ratio of 1.16. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of ACIU (1.16) is worse than 83.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
ACIU Yearly Current Assets VS Current LiabilitesACIU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ACIU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -75.61%.
  • Looking at the last year, ACIU shows a very negative growth in Revenue. The Revenue has decreased by -89.33% in the last year.
  • The Revenue for ACIU have been decreasing by -24.39% on average. This is quite bad
EPS 1Y (TTM)-75.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-420%
Revenue 1Y (TTM)-89.33%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%-96.32%

3.2 Future

  • Based on estimates for the next years, ACIU will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.54% on average per year.
  • The Revenue is expected to grow by 25.22% on average over the next years. This is a very strong growth
EPS Next Y-38.62%
EPS Next 2Y-9.18%
EPS Next 3Y31.96%
EPS Next 5Y15.54%
Revenue Next Year-84.04%
Revenue Next 2Y-2.51%
Revenue Next 3Y46.76%
Revenue Next 5Y25.22%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ACIU Yearly Revenue VS EstimatesACIU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
ACIU Yearly EPS VS EstimatesACIU Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACIU. In the last year negative earnings were reported.
  • Also next year ACIU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACIU Price Earnings VS Forward Price EarningsACIU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACIU Per share dataACIU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • ACIU's earnings are expected to grow with 31.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.18%
EPS Next 3Y31.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ACIU!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AC IMMUNE SA

NASDAQ:ACIU (2/19/2026, 4:10:04 PM)

2.63

+0.01 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-12
Inst Owners24.85%
Inst Owner Change0.4%
Ins Owners3.4%
Ins Owner ChangeN/A
Market Cap264.08M
Revenue(TTM)4.37M
Net Income(TTM)-71.87M
Analysts88
Price Target9.18 (249.05%)
Short Float %5.3%
Short Ratio4.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.03%
Min EPS beat(2)-18%
Max EPS beat(2)17.94%
EPS beat(4)3
Avg EPS beat(4)6.34%
Min EPS beat(4)-18%
Max EPS beat(4)17.94%
EPS beat(8)5
Avg EPS beat(8)-0.9%
EPS beat(12)8
Avg EPS beat(12)-64.44%
EPS beat(16)10
Avg EPS beat(16)-69.05%
Revenue beat(2)1
Avg Revenue beat(2)-11.08%
Min Revenue beat(2)-35.35%
Max Revenue beat(2)13.19%
Revenue beat(4)3
Avg Revenue beat(4)57.1%
Min Revenue beat(4)-35.35%
Max Revenue beat(4)200.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.95%
EPS NY rev (3m)7.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)-1.69%
Revenue NY rev (3m)7.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.53
P/FCF N/A
P/OCF N/A
P/B 3.26
P/tB 16.91
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0.06
BVpS0.81
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.88%
ROE -115.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.15%
Cap/Sales 20.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z -3.58
F-Score2
WACC4.92%
ROIC/WACCN/A
Cap/Depr(3y)38.45%
Cap/Depr(5y)62.34%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-75.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-420%
EPS Next Y-38.62%
EPS Next 2Y-9.18%
EPS Next 3Y31.96%
EPS Next 5Y15.54%
Revenue 1Y (TTM)-89.33%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%-96.32%
Revenue Next Year-84.04%
Revenue Next 2Y-2.51%
Revenue Next 3Y46.76%
Revenue Next 5Y25.22%
EBIT growth 1Y-95.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.67%
EBIT Next 3Y-16.92%
EBIT Next 5Y-6.43%
FCF growth 1Y23.43%
FCF growth 3YN/A
FCF growth 5Y4.12%
OCF growth 1Y24.03%
OCF growth 3YN/A
OCF growth 5Y3.58%

AC IMMUNE SA / ACIU FAQ

Can you provide the ChartMill fundamental rating for AC IMMUNE SA?

ChartMill assigns a fundamental rating of 2 / 10 to ACIU.


Can you provide the valuation status for AC IMMUNE SA?

ChartMill assigns a valuation rating of 1 / 10 to AC IMMUNE SA (ACIU). This can be considered as Overvalued.


How profitable is AC IMMUNE SA (ACIU) stock?

AC IMMUNE SA (ACIU) has a profitability rating of 1 / 10.


What is the financial health of AC IMMUNE SA (ACIU) stock?

The financial health rating of AC IMMUNE SA (ACIU) is 2 / 10.


What is the expected EPS growth for AC IMMUNE SA (ACIU) stock?

The Earnings per Share (EPS) of AC IMMUNE SA (ACIU) is expected to decline by -38.62% in the next year.